BioNTechBNTX
BNTX
About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Employees: 6,772
0
Funds holding %
of 7,429 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
21% more capital invested
Capital invested by funds: $4.71B [Q1] → $5.72B (+$1.01B) [Q2]
0.78% more ownership
Funds ownership: 21.57% [Q1] → 22.35% (+0.78%) [Q2]
0% more repeat investments, than reductions
Existing positions increased: 82 | Existing positions reduced: 82
9% less funds holding
Funds holding: 278 [Q1] → 252 (-26) [Q2]
17% less call options, than puts
Call options by funds: $115M | Put options by funds: $138M
20% less funds holding in top 10
Funds holding in top 10: 5 [Q1] → 4 (-1) [Q2]
39% less first-time investments, than exits
New positions opened: 31 | Existing positions closed: 51
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$110
5%
upside
Avg. target
$136
30%
upside
High target
$155
48%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
HC Wainwright & Co. Robert Burns | 29%upside $136 | Buy Maintained | 14 Aug 2025 |
Wells Fargo Mohit Bansal | 43%upside $150 | Overweight Maintained | 5 Aug 2025 |
B of A Securities Tazeen Ahmad | 28%upside $134 | Buy Maintained | 5 Aug 2025 |
Morgan Stanley Terence Flynn | 27%upside $133 | Overweight Maintained | 10 Jul 2025 |
Truist Securities Asthika Goonewardene | 48%upside $155 | Buy Reiterated | 3 Jun 2025 |
Financial journalist opinion
Based on 15 articles about BNTX published over the past 30 days
Positive
Reuters
2 weeks ago
CureVac settles patent dispute litigation with Pfizer and BioNTech
CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and BioNTech related to mRNA-based COVID-19 vaccines.
Positive
Benzinga
2 weeks ago
These Analysts Revise Their Forecasts On BioNTech After Q2 Results
BioNTech SE BNTX reported a narrower loss for the second quarter on Monday.
Neutral
Seeking Alpha
3 weeks ago
BioNTech SE (BNTX) Q2 2025 Earnings Call Transcript
BioNTech SE (NASDAQ:BNTX ) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Douglas Maffei - Investor Relations Ozlem Tureci - Co-Founder, Chief Medical Officer & Member of Management Board Ramón Zapata-Gomez - CFO & Member of Management Board Ryan Richardson - Chief Strategy Officer, MD & Member of Management Board Ugur Sahin - Co-Founder, CEO & Chair of the Management Board Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Cory William Kasimov - Evercore Inc. Daina Michelle Graybosch - Leerink Partners LLC, Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Tazeen Ahmad - BofA Securities, Research Division Terence C. Flynn - Morgan Stanley, Research Division Operator Welcome to BioNTech Second Quarter 2025 Earnings Call.
Positive
Benzinga
3 weeks ago
BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth
BioNTech SE BNTX reported a second-quarter per-share loss of $1.82 (1.60 euros) on Monday, up from a loss of 3.36 euros reported a year ago, compared to beating the consensus loss of $2.42 per share.
Positive
Barrons
3 weeks ago
BioNTech Stock Rises as Drug Maker Beats Earnings Expectations.
The drug maker reported a narrower-than-expected loss in the second quarter.
Positive
Reuters
3 weeks ago
BioNTech's Q2 revenues double on higher COVID vaccine sales
German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million), driven by higher revenues from its COVID-19 vaccine collaboration with Pfizer.
Neutral
GlobeNewsWire
3 weeks ago
BioNTech Announces Second Quarter 2025 Financial Results and Corporate Update
Continued execution of BioNTech's oncology strategy with focus on two pan-tumor programs including two announced transactions: mRNA-based cancer immunotherapy candidates and BNT327, a bispecific antibody candidate targeting PD-L1 1 and VEGF-A Entered a global strategic co-development and co-commercialization collaboration with Bristol Myers Squibb (“BMS”) to jointly execute a broad clinical development program to evaluate and advance BNT327 across numerous solid tumor types Announced strategic transaction to acquire CureVac N.V. (“CureVac”) to strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates Presented multiple clinical updates across diversified oncology pipeline at medical meetings validating the Company's oncology combination strategy Approval received for new variant-adapted COVID-19 vaccine by the European Commission (“EC”); further launch preparation underway as recommended by regulators, with deliveries expected to be ready as early as August, subject to regulatory approval in respective markets Second quarter 2025 revenues of €0.3 billion2, net loss of €0.4 billion and basic and diluted loss per share of €1.60 ($1.823) Maintained strong financial position with €16.0 billion in cash, cash equivalents and security investments as of June 30, 2025; Partnership with Bristol Myers Squibb expected4 to further strengthen BioNTech's financial position with $1.5 billion expected to be reflected in third quarter 2025 cash position Full year 2025 financial guidance reaffirmed5 Conference call and webcast scheduled for August 4, 2025, at 8:00 a.m.
Neutral
Fast Company
3 weeks ago
Pfizer and BioNTech lose appeal in London over Moderna COVID vaccine patent
Pfizer and its German partner BioNTech on Friday lost their bid to overturn a ruling that their COVID-19 vaccine infringed one of Moderna's patents at London's Court of Appeal.
Positive
CNBC Television
3 weeks ago
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing globally, the future of gene therapy, changes at FDA, and more.
Negative
CNBC Television
3 weeks ago
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
Charts implemented using Lightweight Charts™